Novel engineered protein antagonists of CCR7 that bind CCL21 have been shown to block CCR7-mediated migration of melanoma cells in vitro and in vivo, raising the potential for therapeutically active CCR7 antagonists in patient care [51]. This evidence concerns the gene CCL21 and melanoma.